1 min de lecture
[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.
-
-
Auteurcontact@xenothera.com
-
Publié21 décembre 2022
Articles récents
[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.
December 19, 2022. # Download our press alert (english version) # Télécharger...
More[Newsletter] XENONEWS
November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA
July 11th, 2022. # Download our press information (english version) # Télécharger...
More